Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-332 in Moderate-to-severe Atopic Dermatitis
NCT05702268Phase 2Unknown
- Sponsor
- InnoCare Pharma
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soficitinib in atopic dermatitis (AD), sponsored by InnoCare Pharma. Status: unknown.
02
Drugs
soficitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05702268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702268.